Trial Profile
A Phase 1/2 Study of Apatinib in Combination With AP(Pemetrexed/Cisplatin) or AC(Pemetrexed/Carboplatin) as First-line Chemotherapy for Advanced Epidermal Growth Factor Receptor(EGFR) Wild Type Non-squamous Non-small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Jun 2019 Results assessing phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in non-small cell lung cancer published in the Investigational New Drugs
- 30 Jun 2017 New trial record